<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04629248</url>
  </required_header>
  <id_info>
    <org_study_id>WA41937</org_study_id>
    <secondary_id>2020-003233-38</secondary_id>
    <nct_id>NCT04629248</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy</brief_title>
  <official_title>A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of&#xD;
      obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy&#xD;
      (pMN).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">January 9, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants who Achieve a Complete Remission (CR) at Week 104</measure>
    <time_frame>Week 104</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve an Overall Remission at Week 104</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve CR at Week 76</measure>
    <time_frame>Week 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure, Meeting Escape Criteria, or Relapse after Complete or Partial Remission</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to a Sustained Reduction of Estimated Glomerular Filtration Rate (eGFR) &gt;= 30% from Baseline</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in T-score from Baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale at Week 104</measure>
    <time_frame>Baseline to Week 104</time_frame>
    <description>Self-reported changes in fatigue will be measured using the PROMIS Fatigue Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CR</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anti-PLA2R Autoantibody Titer</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the PROMIS Global Assessment of Physical Health Scale at Week 104</measure>
    <time_frame>Baseline to Week 104</time_frame>
    <description>Self-reported changes in physical health will be measured using the PROMIS Physical Health Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with AEs of Special Interest (AESIs)</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>AESIs are required to be reported by the investigator to the Sponsor immediately</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral B-cell Counts at Specified Timepoints</measure>
    <time_frame>Weeks 0 (baseline), 2, 4, 12, 24, 26, 36, 52, 64, 76, 88, 104, 117, 130, 156, 182, 208 and every 26 weeks thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Obinutuzumab at Specified Timepoints</measure>
    <time_frame>Weeks 0 (baseline), 2, 4, 12, 24, 26, 36, 52, 64, 76, 88, 104, 117, 130, 143, 156, 169, 182, 195, 208, every 26 weeks thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Anti-drug Antibodies (ADAs) to Obinutuzumab at Baseline</measure>
    <time_frame>Open Label: Baseline; Escape Treatment: Week 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ADAs during the study</measure>
    <time_frame>Weeks 2, 4, 12, 24, 26, 36, 52, 64, 76, 88, 104, 130, 156, 182, 208 and every 26 weeks thereafter</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Primary Membranous Nephropathy</condition>
  <arm_group>
    <arm_group_label>Open Label Treatment: Obinutuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized at a 1:1 ratio to receive open-label treatment with obinutuzumab according to region and anti-phospholipase A2 receptor (PLA2R) autoantibody titer (using Euroimmun ELISA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open Label Treatment: Tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomized at a 1:1 ratio to receive open-label treatment with tacrolimus according to region and anti-PLA2R autoantibody titer (using Euroimmun ELISA).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Open Label: An intravenous (IV) infusion of 1000 milligram (mg) of obinutuzumab will be administered at Week 0, Week 2, Week 24, and Week 26. Participants who relapse during the open-label treatment period may be eligible for further treatment.</description>
    <arm_group_label>Open Label Treatment: Obinutuzumab</arm_group_label>
    <other_name>Gazyva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Open Label: Participants will receive tacrolimus at a starting oral dose (PO) of 0.05 mg/kilogram (kg) (participant dry weight) per day divided into two equal doses given at 12-hour intervals, titrated to serum trough level 5-7 Nanograms per millilitre (ng/mL). Optimized tacrolimus dose will be maintained for a maximum 52 weeks dependent on response and then tapered over 8 weeks. Participants who relapse during the open-label treatment period will have their dose of tacrolimus tapered over 8 weeks and may be eligible for further treatment.</description>
    <arm_group_label>Open Label Treatment: Tacrolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Premedication: Methylprednisolone 80 mg IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.</description>
    <arm_group_label>Open Label Treatment: Obinutuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Premedication: Acetaminophen (650-1000 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.</description>
    <arm_group_label>Open Label Treatment: Obinutuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>Premedication: Diphenhydramine (50 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.</description>
    <arm_group_label>Open Label Treatment: Obinutuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of primary membranous nephropathy (pMN) according to renal biopsy prior to&#xD;
             or during screening&#xD;
&#xD;
          -  Urinary protein-to-creatinine ratio (UPCR) &gt;= 5 g/g from 24-hour urine collection&#xD;
             despite best supportive care for &gt;= 3 months prior to screening or UPCR &gt;= 4 g/g&#xD;
             despite best supportive care &gt;= 6 months prior to screening&#xD;
&#xD;
          -  eGFR &gt;= 40 mL/min/1.73m^2 or qualified endogenous creatinine clearance &gt;= 40&#xD;
             mL/min/1.73m^2 based on 24-hour urine collection during screening&#xD;
&#xD;
          -  Other inclusion criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with a secondary cause of MN&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Evidence of &gt;= 50% reduction in proteinuria during the previous 6 months prior to&#xD;
             randomization&#xD;
&#xD;
          -  Severe renal impairment, including the need for dialysis or renal replacement therapy&#xD;
&#xD;
          -  Type 1 or 2 diabetes mellitus&#xD;
&#xD;
          -  Receipt of an excluded therapy, including any anti-CD20 therapy less than 9 months&#xD;
             prior to or during screening; or cyclophosphamide, tacrolimus, or cyclosporin less&#xD;
             than 6 months prior to or during screening&#xD;
&#xD;
          -  Significant or uncontrolled medical disease which, in the investigator's opinion,&#xD;
             would preclude participant participation&#xD;
&#xD;
          -  Known active infection of any kind or recent major episode of infection&#xD;
&#xD;
          -  Major surgery requiring hospitalization within the 4 weeks prior to screening&#xD;
&#xD;
          -  Current active alcohol or drug abuse or history of alcohol or drug abuse within 12&#xD;
             months prior to screening&#xD;
&#xD;
          -  Intolerance or contraindication to study therapies&#xD;
&#xD;
          -  Other exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: WA41937 http://www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>mailto:global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aventiv Research Inc</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keck School of Medicine - University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Accel Research Sites; Mid-Florida Kidney and Hypertension Care</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Loyola University Med Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center in New Orleans; Section of Nephrology</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital; Div of Nephrology &amp; Hypertension</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic; Nephrology and Hypertension</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penn State Univ. Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prolato Clinical Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CINME</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1056</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Organizacion Medica de Investigacion</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Britanico Buenos Aires; Rheumatology Service</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires; Rheumatology department</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <zip>C1199ABD</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ser Servicos Especializados Em Reumatologia</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <zip>40150-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Base de Sao Jose do Rio Preto</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>SP</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital do Rim e Hipertensão - Fundação Oswaldo Ramos</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04038-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - FMUSP; Nefrologia</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing City</city>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing City</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital - Sichuan University</name>
      <address>
        <city>Chengdu City</city>
        <zip>610047</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <zip>610072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The 1st Affiliated hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou City</city>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chinese People's Liberation Army Eastern Theater General Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai City</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital, Fudan University</name>
      <address>
        <city>Shanghai City</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan City</city>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xian Jiao Tong University</name>
      <address>
        <city>Xi'an City</city>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <zip>750004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital La Cavale Blanche; Nephrologie</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HOPITAL HENRI MONDOR; SERVICE DE Nephrologie</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat Claude Bernard; Nephrologie</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon; Nephrologie Dialyse</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Rangueil; Service de Nephrologie &amp; D'Immunologie Clinique</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center; Department of Nephrology and Hypertension</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Orgainastion; Nephrology</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheba MC; Nephrology</name>
      <address>
        <city>Ramat-Gan</city>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. U. Federico II; U.O. di Nefrologia - Dipartimento di Sanità Pubblica</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Spedali Civili Di Brescia-P.O. Spedali Civili; Nefrologia</name>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Monza - Ospedale San Gerardo; Clinica Nefrologica</name>
      <address>
        <city>Monza</city>
        <state>Lombardia</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Bosco; Unita Operativa Nefrologia Dialisi</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10154</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico di Bari; Divisione di Nefrologia, Dialisi e Trapianto</name>
      <address>
        <city>Bari</city>
        <state>Puglia</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Alberto Sabogal Sologuren</name>
      <address>
        <city>Callao</city>
        <zip>Callao 02</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Internacional - Sede San Borja</name>
      <address>
        <city>San Borja</city>
        <zip>15036</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Peruana Americana</name>
      <address>
        <city>Trujillo</city>
        <zip>13011</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny w Bialymstoku; II Klinika Nefrologii</name>
      <address>
        <city>Białystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki im.dr.A.Jurasza w Bydgoszczy; Klinika Nefrologii, Nadcisnienia Tetniczego</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SPSK Slaskiego UM w Katowicach; Katedra i Klinika Nefrologii, Endokryn.I Chorob Przemiany Materii</name>
      <address>
        <city>Katowice</city>
        <zip>40-027</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu; Klinika Nefrologii</name>
      <address>
        <city>Wrocław</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny nr 1 im. N. Barlickiego; Oddzial Nefrologii</name>
      <address>
        <city>Łódź</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny im WAM CSW; Klinika Nefrologii i Transplantologii Nerek</name>
      <address>
        <city>Łódź</city>
        <zip>92-213</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Autonomous non-commercial organization &quot;Medical Research Center of Drug Therapy &quot;Yuninova&quot;</name>
      <address>
        <city>Sankt-peterburg</city>
        <state>Sankt Petersburg</state>
        <zip>194156</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>German clinic</name>
      <address>
        <city>Sankt-peterburg</city>
        <state>Sankt Petersburg</state>
        <zip>196128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Moscow State Medical University n.a. I.M. Sechenov</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rostov State Medical Uni ; Hematology</name>
      <address>
        <city>Rostov-na-donu</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge; Servicio de Nefrologia</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron; Servicio de Nefrologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial; Servicio de Nefrologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitaro Gregorio Marañon ;Servicio de Nefrologia</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre; Servicio de Nefrologia</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset; Servicio de Nefrologia</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hacettepe Uni School of Medicine; Nephrology</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akdeniz University Medical Faculty; Internal Medicine, Nephrology</name>
      <address>
        <city>Antalya</city>
        <zip>07059</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istanbul University Istanbul Medical Faculty; Department of Internal Medicine</name>
      <address>
        <city>Istanbul</city>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ege Uni School of Medicine; Nephrology</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istanbul Florence Nightingale Hospital; Nephrology</name>
      <address>
        <city>Şi̇şli̇</city>
        <zip>34381</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ternopil University Hospital</name>
      <address>
        <city>Ternopil</city>
        <state>Kherson Governorate</state>
        <zip>46002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oleksandrivska Clinical Hospital</name>
      <address>
        <city>Kyiv</city>
        <state>KIEV Governorate</state>
        <zip>01023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital n.a I.I. Mechnicov</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Nephrology NAMS of Ukraine; Department of Nephrology, Dialysis and IT Support</name>
      <address>
        <city>Kiev</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>China</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

